Stock PPLPHARMA PIRAMAL PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Piramal Pharma Limited

Equities

PPLPHARMA

INE0DK501011

Delayed NSE India S.E.
Other stock markets
 01:24:59 2024-06-27 EDT 		5-day change 1st Jan Change
157.5 INR +0.40% Intraday chart for Piramal Pharma Limited +1.53% +13.53%
05-14 Jefferies Adjusts Piramal Pharma’s Price Target to INR180 From INR170, Keeps at Buy MT
05-13 Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 47% by 2026.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 209.19 times its estimated earnings per share for the ongoing year.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PIRAMAL PHARMA LIMITED Stock Piramal Pharma Limited
+13.53% 2.49B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 811B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 640B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 333B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 246B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 225B
A+
NOVARTIS AG Stock Novartis AG
+13.03% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.61% 168B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PPLPHARMA Stock
  4. Ratings Piramal Pharma Limited